Here, we focus on the proteasome inhibitor, Bortezomib (Velcade®, Millennium Pharmaceuticals) and other promising NFκB inhibitors in clinical trials for treatment of AML. The gene discussed is NFKB1; the disease is acute myeloid leukemia.